Skip Navigation

Percutaneous radiofrequency ablation for primary and secondary lung cancers

Guidance issued Guidance issued
 
IP Guidance Number: IPG185
 
Summary:
The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on Percutaneous radiofrequency ablation for primary and secondary lung cancers.
Description:

Both primary lung cancer, and metastatic lung disease are common. The stage of the disease is the most important prognostic factor; however, the overall prognosis for patients with lung cancer is poor. Percutaneous radiofrequency ablation may be used in patients with small early-stage lung cancer for whom surgery is not appropriate or who do not wish to undergo conventional surgery, and for patients with a small number of lung metastases

A small needle electrode is inserted through the skin directly into the tumour, usually under computed tomography (CT) guidance. Radiofrequency energy is passed through the electrode, producing heat which destroys the tumour tissue.

Arrangements:

Other (see guidance)

Topic Area:

Cancer
Respiratory

Specialty:

Clinical oncology
Medical oncology

Specialist advice has
been sought from:

British Society of Interventional Radiology

Royal College of Radiologists

British Thoracic Society

Society of Cardiothoracic Surgeons of GB & Ireland

Date notified to NICE: 21 February 2005
Provisional Consultation Date: Autumn 2005
Guidance Publication Date: 26 July 2006
Contact Details:
Technical Lead
(for procedure specific enquiries or comments)
Kan Choy
ip@nice.org.uk
Contact Address:

Interventional Procedures Programme
National Institute for Health and Clinical Excellence
MidCity Place
71 High Holborn
London
WC1V 6NA


Links:

Search NICE guidance


Advanced guidance search

Related information

See NICE guidance in practice

Related guidance

Click the links below to see guidance on similar topics